Market Overview:
The global personalizing cancer drugs market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, technological advancements in the field of personalized cancer drugs, and rising demand for targeted therapies. Based on type, the global personalizing cancer drugs market is segmented into immunotherapy, targeted therapy, chemotherapy, hormone therapy, and others. Immunotherapy is expected to be the fastest-growing segment during the forecast period owing to its ability to target various types of cancers and its growing popularity among patients. By application, breast cancer is expected to be the largest segment in terms of revenue during the forecast period followed by blood cancer and gastrointestinal cancer.
Product Definition:
Personalizing cancer drugs is the process of adjusting the dosage and treatment plan for an individual patient, based on their unique characteristics. This includes factors such as age, weight, general health and cancer type. Personalized cancer drugs are important because they can help to ensure that each patient receives the most effective treatment possible.
Immunotherapy:
Immunotherapy is a branch of biological therapy which aims at stimulating the body's immune system to fight cancer. The treatment works by increasing the white blood cells and other immune system components such as T-cell, natural killer cell, B-cell and antibody. These cells act as sentries that identify foreign particles (tumor) in the body and attack & destroy them. This process aids in decreasing tumor size & number as well as improves patient survival rates by quite a bit.
Targeted Therapy:
Targeted therapy is a type of cancer treatment that attacks and eliminates specific cancer cells. It also helps in minimizing the side effects of the medicine used for treating the disease. Targeted therapies are gaining popularity among oncologists as well as patients owing to its several advantages over traditional chemotherapy and radiation techniques. Some major advantages include minimum damage to healthy tissues, ability to target only cancer cells, minimal or no side effects, etc.
Application Insights:
The breast cancer segment dominated the global market in 2017 owing to the increasing prevalence of breast cancer and high treatment rates. Breast cancer is one of the most common types of cancers found in women, accounting for around 25% to 30% of all diagnosed cases globally every year. According to Breastcancer.org, an online resource dedicated to providing information on breast health and related diseases, around 1 in 8 U.S women develop invasive ductal carcinoma (IDC) during her lifetime while about 2-3 out of 10 U.S women die from it each year after diagnosis as well as before reaching retirement age due to lack of proper healthcare facilities and early detection methods available for this disease across the globe thus driving its demand globally over recent years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; coupled with high R&D investments by these companies. In addition, rising incidence rates of cancer are also expected to boost regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to increasing healthcare expenditure levels in emerging economies like China and India along with growing patient awareness levels pertaining personalizing medicine approaches for treatment selection & development of effective treatment strategies for oncological diseases. Moreover, rapidly improving healthcare infrastructure facilities including research laboratories and clinical care centers will support regional growth further over next eight years (2018-2030). Global personalized medicine drugs market share, by application segment, 2018 (%)Global personalized medicine drugs market share by region (U.S.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is primarily due to the aging population and the rising prevalence of lifestyle-related cancers. According to a study by the American Cancer Society, the number of new cases of cancer is expected to rise from 14 million in 2012 to 22 million by 2030. This will create a large pool of patients who will require personalized cancer drugs for treatment.
- Advances in technology: The development and application of novel technologies such as next-generation sequencing (NGS) and proteomics are helping researchers identify biomarkers that can be used for personalizing cancer drugs. These technologies are also helping researchers develop targeted therapies that are more effective than traditional chemotherapy regimens.
- Growing demand for precision medicine: There is growing demand for precision medicine, which involves tailoring treatments according to an individual’s genetic makeup or other specific characteristics. Precision medicine has been shown to be more effective than traditional treatments in many cases, and this has led to its growing adoption across healthcare settings worldwide. Personalized cancer drugs are a key component of precision medicine initiatives aimed at treating patients with cancers that have proven resistant to traditional therapies .
Scope Of The Report
Report Attributes
Report Details
Report Title
Personalizing Cancer Drugs Market Research Report
By Type
Immunotherapy, Targeted Therapy, Chemotherapy, Hormone Therapy, Others
By Application
Breast Cancer, Blood Cancer, Gastrointestinal Cancer, Prostate Cancer, Skin Cancer, Lung Cancer, Others
By Companies
Bayer, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Amgen, Merck, Bristol-Myers Squibb, Celgene Corporation, Ariad Pharmaceuticals, Eli Lilly, Hoffmann-La Roche, Boehringer Ingelheim, Johnson and Johnson, Teva Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
141
Number of Tables & Figures
99
Customization Available
Yes, the report can be customized as per your need.
Global Personalizing Cancer Drugs Market Report Segments:
The global Personalizing Cancer Drugs market is segmented on the basis of:
Types
Immunotherapy, Targeted Therapy, Chemotherapy, Hormone Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Blood Cancer, Gastrointestinal Cancer, Prostate Cancer, Skin Cancer, Lung Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- GlaxoSmithKline
- Novartis
- Sanofi
- Pfizer
- Amgen
- Merck
- Bristol-Myers Squibb
- Celgene Corporation
- Ariad Pharmaceuticals
- Eli Lilly
- Hoffmann-La Roche
- Boehringer Ingelheim
- Johnson and Johnson
- Teva Pharmaceuticals
Highlights of The Personalizing Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Hormone Therapy
- Others
- By Application:
- Breast Cancer
- Blood Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Skin Cancer
- Lung Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Personalizing Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Personalizing cancer drugs means tailoring the drug to the individual's specific cancer type and tumor. This can involve adjusting the dosage, adding or removing ingredients, or changing how the drug is delivered.
Some of the major players in the personalizing cancer drugs market are Bayer, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Amgen, Merck, Bristol-Myers Squibb, Celgene Corporation, Ariad Pharmaceuticals, Eli Lilly, Hoffmann-La Roche, Boehringer Ingelheim, Johnson and Johnson, Teva Pharmaceuticals.
The personalizing cancer drugs market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Personalizing Cancer Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Personalizing Cancer Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Personalizing Cancer Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Personalizing Cancer Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Personalizing Cancer Drugs Market Size & Forecast, 2020-2028
4.5.1 Personalizing Cancer Drugs Market Size and Y-o-Y Growth
4.5.2 Personalizing Cancer Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Immunotherapy
5.2.2 Targeted Therapy
5.2.3 Chemotherapy
5.2.4 Hormone Therapy
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Breast Cancer
6.2.2 Blood Cancer
6.2.3 Gastrointestinal Cancer
6.2.4 Prostate Cancer
6.2.5 Skin Cancer
6.2.6 Lung Cancer
6.2.7 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Personalizing Cancer Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Personalizing Cancer Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Immunotherapy
9.6.2 Targeted Therapy
9.6.3 Chemotherapy
9.6.4 Hormone Therapy
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Breast Cancer
9.10.2 Blood Cancer
9.10.3 Gastrointestinal Cancer
9.10.4 Prostate Cancer
9.10.5 Skin Cancer
9.10.6 Lung Cancer
9.10.7 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Immunotherapy
10.6.2 Targeted Therapy
10.6.3 Chemotherapy
10.6.4 Hormone Therapy
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Breast Cancer
10.10.2 Blood Cancer
10.10.3 Gastrointestinal Cancer
10.10.4 Prostate Cancer
10.10.5 Skin Cancer
10.10.6 Lung Cancer
10.10.7 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Immunotherapy
11.6.2 Targeted Therapy
11.6.3 Chemotherapy
11.6.4 Hormone Therapy
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Breast Cancer
11.10.2 Blood Cancer
11.10.3 Gastrointestinal Cancer
11.10.4 Prostate Cancer
11.10.5 Skin Cancer
11.10.6 Lung Cancer
11.10.7 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Immunotherapy
12.6.2 Targeted Therapy
12.6.3 Chemotherapy
12.6.4 Hormone Therapy
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Breast Cancer
12.10.2 Blood Cancer
12.10.3 Gastrointestinal Cancer
12.10.4 Prostate Cancer
12.10.5 Skin Cancer
12.10.6 Lung Cancer
12.10.7 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Immunotherapy
13.6.2 Targeted Therapy
13.6.3 Chemotherapy
13.6.4 Hormone Therapy
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Breast Cancer
13.10.2 Blood Cancer
13.10.3 Gastrointestinal Cancer
13.10.4 Prostate Cancer
13.10.5 Skin Cancer
13.10.6 Lung Cancer
13.10.7 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Personalizing Cancer Drugs Market: Competitive Dashboard
14.2 Global Personalizing Cancer Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 GlaxoSmithKline
14.3.3 Novartis
14.3.4 Sanofi
14.3.5 Pfizer
14.3.6 Amgen
14.3.7 Merck
14.3.8 Bristol-Myers Squibb
14.3.9 Celgene Corporation
14.3.10 Ariad Pharmaceuticals
14.3.11 Eli Lilly
14.3.12 Hoffmann-La Roche
14.3.13 Boehringer Ingelheim
14.3.14 Johnson and Johnson
14.3.15 Teva Pharmaceuticals
